Abstract:Sphingomyelin plays a very important role both in cell membrane formation that may well have an impact on the development of diseases like atherosclerosis and diabetes. However, the molecular mechanism that governs intracellular and plasma membrane SM levels is largely unknown. Recently, two isoforms of sphingomyelin synthase (SMS1 and SMS2), the last enzyme for SM de novo synthesis, have been cloned. We have hypothesized that SMS1 and SMS2 are the two most likely candidates responsible for the SM levels in the cells and on the plasma membrane. To test this hypothesis, cultured cells were treated with tricyclodecan-9-yl-xanthogenate (D609), an inhibitor of SMS, or with SMS1 and SMS2 siRNAs. Cells were then pulsed with [14C]-L-serine (a precursor of all sphingolipids). SMS activity and [14C]-SM in the cells were monitored. We found that SMS activity was significantly decreased in cells after D609 or SMS siRNA treatment, compared with controls. SMS inhibition by D609 or SMS siRNAs significantly decreased intracellular [14C]-SM levels. We measured cellular lipid levels, including SM, ceramide, phosphatidylcholine, and diacylglycerol and found that SMS1 and SMS2 siRNA treatment caused a significant decrease of SM levels (20% and 11%, respectively), compared to control siRNA treatment; SMS1 but not SMS2 siRNA treatment caused a significant increase of ceramide levels (10%). There was a decreasing tendency for diacylglycerol levels after both SMS1 and SMS2 siRNA treatment, however, it was not statistical significant. As shown by lipid rafts isolation and lipid determination, SMS1 and SMS2 siRNA treatment led to a decrease of SM content in detergent-resistant lipid rafts on the cell membrane. Furthermore, SMS1 and SMS2 siRNA-treated cells had a stronger resistance than did control siRNA-treated cells to lysenin (a protein that causes cell lysis due to its affinity for plasma membrane SM). These results indicate that both SMS1 and SMS2 contribute to SM de novo synthesis and control SM levels in the cells and on the cell membrane including plasma membrane, implying an important relationship between SMS activity and cell functions.

Cryo-EM Structure of Human Sphingomyelin Synthase and Its Mechanistic Implications for Sphingomyelin Synthesis

Molecular Modeling of the Three-Dimensional Structure of Human Sphingomyelin Synthase

Molecular Basis for the Catalytic Mechanism of Human Neutral Sphingomyelinases 1 (Hsmpd2).

The Sphingomyelin Synthase Family: Proteins, Diseases, and Inhibitors

Resolving Modifications on Sphingoid Base and N-Acyl Chain of Sphingomyelin Lipids in Complex Lipid Extracts

Sphingomyelin Synthase Family and Phospholipase Cs

The domain responsible for sphingomyelin synthase (SMS) activity.

Development of a Quantitative Biochemical and Cellular Sphingomyelin Synthase Assay Using Mass Spectrometry

Structural insights into the regulation of human serine palmitoyltransferase complexes

All Members in the Sphingomyelin Synthase Gene Family Have Ceramide Phosphoethanolamine Synthase Activity

Sphingomyelin Synthase Related Protein is a Mammalian Phosphatidylethanolamine Phospholipase C

Inhibition of Sphingomyelin Synthase (SMS) Affects Intracellular Sphingomyelin Accumulation and Plasma Membrane Lipid Organization.

Ceramide sensing by human SPT-ORMDL complex for establishing sphingolipid homeostasis

Functional Characterization of Enzymes Catalyzing Ceramide Phosphoethanolamine Biosynthesis in Mice

Structure of the yeast ceramide synthase

Structural insights into the assembly and substrate selectivity of human SPT–ORMDL3 complex

Subcellular Targeting Domains of Sphingomyelin Synthase 1 and 2

Sphingomyelin Synthases 1 and 2 Exhibit Phosphatidylcholine Phospholipase C Activity

Structure and Interaction of Ceramide-Containing Liposomes with Gold Nanoparticles As Characterized by SERS and Cryo-EM

Mechanisms Involved in Cellular Ceramide Homeostasis

Insights into Membrane Association of the SMP Domain of Extended Synaptotagmin.